The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Systemic Administration of PRO051 in Duchenne's Muscular Dystrophy
Open accessAbstract
BACKGROUND: Local intramuscular administration of the antisense oligonucleotide PRO051 in patients with Duchenne's muscular dystrophy with relevant mutations was previously reported to induce the skipping of exon 51 during pre-messenger RNA splicing of the dystrophin gene and to facilitate new dystrophin expression in muscle-fiber membranes. The present phase 1-2a study aimed to assess the safety, pharmacokinetics, and molecular and clinical effects of systemically administered PRO051. METHODS: We administered weekly abdominal subcutaneous injections of PRO051 for 5 weeks in 12 patients, with each of four possible doses (0.5, 2.0, 4.0, and 6.0 mg per kilogram of body weight) given to 3 patients. Changes in RNA splicing and protein levels in the tibialis anterior muscle were assessed at two time points. All patients subsequently entered a 12-week open-label extension phase, during which they all received PRO051 at a dose of 6.0 mg per kilogram per week. Safety, pharmacokinetics, serum creatine kinase levels, and muscle strength and function were assessed. RESULTS: The most common adverse events were irritation at the administration site and, during the extension phase, mild and variable proteinuria and increased urinary α(1)-microglobulin levels; there were no serious adverse events. The mean terminal half-life of PRO051 in the circulation was 29 days. PRO051 induced detectable, specific exon-51 skipping at doses of 2.0 mg or more per kilogram. New dystrophin expression was observed between approximately 60% and 100% of muscle fibers in 10 of the 12 patients, as measured on post-treatment biopsy, which increased in a dose-dependent manner to up to 15.6% of the expression in healthy muscle. After the 12-week extension phase, there was a mean (±SD) improvement of 35.2±28.7 m (from the baseline of 384±121 m) on the 6-minute walk test. CONCLUSIONS: Systemically administered PRO051 showed dose-dependent molecular efficacy in patients with Duchenne's muscular dystrophy, with a modest improvement in the 6-minute walk test after 12 weeks of extended treatment. (Funded by Prosensa Therapeutics; Netherlands National Trial Register number, NTR1241.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Emery, A. E. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07815-7 · Cited by 1,667
Population frequencies of inherited neuromuscular diseases—A world survey
Emery, A. E. H. (1991) · Neuromuscular Disorders · doi:10.1016/0960-8966(91)90039-u · Cited by 1,448
Monaco, A. P., Bertelson, C. J., Liechti-Gallati, S., Moser, H., & Kunkel, L. M. (1988) · Genomics · doi:10.1016/0888-7543(88)90113-9 · Cited by 1,210
Dystrophin and mutations: one gene, several proteins, multiple phenotypes
Muntoni, F., Torelli, S., & Ferlini, A. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00585-4 · Cited by 1,124
McDonald, C. M., Abresch, R. T., Carter, G. T., Fowler, W. M., Johnson, E. R., Kilmer, D. D., & Sigford, B. J. (1995) · American Journal of Physical Medicine & Rehabilitation · doi:10.1097/00002060-199509001-00003 · Cited by 1,069
Koenig, M., Beggs, A. H., Moyer, M., Scherpf, S., Heindrich, K., Bettecken, T., Meng, G., Müller, C. R., Lindlöf, M., Kääriäinen, H. A., et al. (1989) · Europe PMC (PubMed Central) · Cited by 961
Hoffman, E. P., Fischbeck, K. H., Brown, R. H., Johnson, M., Medori, R., Loire, J. D., Harris, J. B., Waterston, R., Brooke, M., Specht, L., et al. (1988) · New England Journal of Medicine · doi:10.1056/nejm198805263182104 · Cited by 927
Local Dystrophin Restoration with Antisense Oligonucleotide PRO051
van Deutekom, J. C., Janson, A. A., Ginjaar, I. B., Frankhuizen, W. S., Aartsma-Rus, A., Bremmer-Bout, M., den Dunnen, J. T., Koop, K., van der Kooi, A. J., Goemans, N. M., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa073108 · Cited by 781
Self-citationAartsma‐Rus, A., Van Deutekom, J. C. T., Fokkema, I. F., Van Ommen, G. B., & Den Dunnen, J. T. (2006) · Muscle & Nerve · doi:10.1002/mus.20586 · Cited by 739
Self-citationVery mild muscular dystrophy associated with the deletion of 46% of dystrophin
England, S. B., Nicholson, L. V. B., Johnson, M. A., Forrest, S. M., Love, D. R., Zubrzycka-Gaarn, E. E., Bulman, D. E., Harris, J. B., & Davies, K. E. (1990) · Nature · doi:10.1038/343180a0 · Cited by 623
Aartsma-Rus, A., Fokkema, I., Verschuuren, J., Ginjaar, I., van Deutekom, J., van Ommen, G.-J., & den Dunnen, J. T. (2009) · Human Mutation · doi:10.1002/humu.20918 · Cited by 575
Self-citationThe 6‐minute walk test as a new outcome measure in Duchenne muscular dystrophy
McDonald, C. M., Henricson, E. K., Han, J. J., Abresch, R. T., Nicorici, A., Elfring, G. L., Atkinson, L., Reha, A., Hirawat, S., & Miller, L. L. (2010) · Muscle & Nerve · doi:10.1002/mus.21544 · Cited by 397
Antisense oligonucleotide pharmacokinetics and metabolism
Geary, R. S. (2009) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425250902877680 · Cited by 300
Therapeutic antisense-induced exon skipping in cultured muscle cells from six different DMD patients
Aartsma-Rus, A. (2003) · Human Molecular Genetics · doi:10.1093/hmg/ddg100 · Cited by 253
Self-citationEscolar, D. M., Henricson, E. K., Mayhew, J., Florence, J., Leshner, R., Patel, K. M., & Clemens, P. R. (2001) · Muscle & Nerve · doi:10.1002/mus.1070 · Cited by 251
Lu, Q. L., Morris, G. E., Wilton, S. D., Ly, T., Artem'yeva, O. V., Strong, P., & Partridge, T. A. (2000) · The Journal of Cell Biology · doi:10.1083/jcb.148.5.985 · Cited by 197
Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy
Aartsma-Rus, A., Bremmer-Bout, M., Janson, A. A. M., den Dunnen, J. T., van Ommen, G.-J. B., & van Deutekom, J. C. T. (2002) · Neuromuscular Disorders · doi:10.1016/s0960-8966(02)00086-x · Cited by 175
Self-citationThe 6‐minute walk test in Duchenne/Becker muscular dystrophy: Longitudinal observations
MCDonald, C. M., Henricson, E. K., Han, J. J., Abresch, R. T., Nicorici, A., Atkinson, L., Elfring, G. L., Reha, A., & Miller, L. L. (2010) · Muscle & Nerve · doi:10.1002/mus.21808 · Cited by 172
Guidelines for Antisense Oligonucleotide Design and Insight Into Splice-modulating Mechanisms
Aartsma-Rus, A. M., van Vliet, L., Hirschi, M., Janson, A. A. M., Heemskerk, H., de Winter, C. L., de Kimpe, S. J., van Deutekom, J. C. T., Hoen, P. A. C. ’., & van Ommen, G. B. (2008) · Molecular Therapy · doi:10.1038/mt.2008.205 · Cited by 147
Self-citationHeemskerk, H., de Winter, C., van Kuik‐Romeijn, P., Heuvelmans, N., Sabatelli, P., Rimessi, P., Braghetta, P., van Ommen, G. B., de Kimpe, S. J., Ferlini, A., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.72 · Cited by 141
Self-citationYu, R. Z., Baker, B. F., Chappell, A. E., Geary, R. S., Cheung, E., & Levin, A. A. (2002) · Analytical Biochemistry · doi:10.1006/abio.2002.5576 · Cited by 138
Reliable surrogate outcome measures in multicenter clinical trials of Duchenne muscular dystrophy
Mayhew, J. E., Florence, J. M., Mayhew, T. P., Henricson, E., Leshner, R. T., McCarter, R., Escolar, D. M., & and The CINRG Investigators (2006) · Muscle & Nerve · doi:10.1002/mus.20654 · Cited by 123
Exon skipping and translation in patients with frameshift deletions in the dystrophin gene.
Sherratt, T. G., Vulliamy, T., Dubowitz, V., Sewry, C. A., & Strong, P. N. (1993) · Europe PMC (PubMed Central) · Cited by 92
The therapeutic potential of antisense-mediated exon skipping.
van Ommen, G. B., van Deutekom, J., & Aartsma-Rus, A. M. (2008) · PubMed · Cited by 83
Self-citationMelis, M., Cau, M., Muntoni, F., Mateddu, A., Galanello, R., Boccone, L., Deidda, F., Loi, D., & Cao, A. (1998) · European Journal of Paediatric Neurology · doi:10.1016/s1090-3798(98)80039-1 · Cited by 69
den Enden, A. T. J. M. H.-V., Straathof, C. S. M., Aartsma-Rus, A. M., den Dunnen, J. T., Verbist, B. M., Bakker, E., Verschuuren, J. J. G. M., & Ginjaar, H. B. (2010) · Neuromuscular Disorders · doi:10.1016/j.nmd.2010.01.013 · Cited by 62
Self-citationBasic Principles of the Pharmacokinetics of Antisense Oligonucleotide Drugs
Yu, R., Geary, R., & Levin, A. (2007) · CRC Press eBooks · doi:10.1201/9780849387951-14 · Cited by 59
Immune rejection of human dystrophin following intramuscular injections of naked DNA in mdx mice
Braun, S., Thioudellet, C., Rodriguez, P., Ali-Hadji, D., Perraud, F., Accart, N., Balloul, J.-M., Halluard, C., Acres, B., Cavallini, B., et al. (2000) · Gene Therapy · doi:10.1038/sj.gt.3301261 · Cited by 49
Nguyen, T. M., Ginjaar, I. B., van Ommen, G. B., & Morris, G. E. (1992) · Biochemical Journal · doi:10.1042/bj2880663 · Cited by 40
The “rescue” of dystrophin synthesis in boys with Duchenne muscular dystrophy
Nicholson, L. V. B. (1993) · Neuromuscular Disorders · doi:10.1016/0960-8966(93)90109-w · Cited by 31
Cited by
In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy
Nelson, C. E., Hakim, C. H., Ousterout, D. G., Thakore, P. I., Moreb, E. A., Rivera, R. M. C., Madhavan, S., Pan, X., Ran, F. A., Yan, W. X., et al. (2016) · Science · doi:10.1126/science.aad5143 · Cited by 1,144
RNA therapeutics: beyond RNA interference and antisense oligonucleotides
Kole, R., Krainer, A. R., & Altman, S. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3625 · Cited by 1,152
Non-coding RNAs as drug targets
Matsui, M., & Corey, D. R. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.117 · Cited by 1,032
Cirak, S., Arechavala-Gomeza, V., Guglieri, M., Feng, L., Torelli, S., Anthony, K., Abbs, S., Garralda, M. E., Bourke, J., Wells, D. J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60756-3 · Cited by 878
Evidence-based path to newborn screening for Duchenne muscular dystrophy
Mendell, J. R., Shilling, C., Leslie, N. D., Flanigan, K. M., al‐Dahhak, R., Gastier‐Foster, J., Kneile, K., Dunn, D. M., Duval, B., Aoyagi, A., et al. (2012) · Annals of Neurology · doi:10.1002/ana.23528 · Cited by 813
Metadata
- Authors
- Goemans, N. M., Tulinius, M., van den Akker, J. T., Burm, B. E., Ekhart, P. F., Heuvelmans, N., Holling, T., Janson, A. A., Platenburg, G. J., Sipkens, J. A., Sitsen, J. M. A., Aartsma-Rus, A., van Ommen, G.-J. B., Buyse, G., Darin, N., Verschuuren, J. J., Campion, G. V., de Kimpe, S. J., & van Deutekom, J. C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-04-21
- Volume
- 364
- Issue
- 16
- Pages
- 1513-1522
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2117224856
- Cited by
- 678
- References
- 30
- FWCI
- 37.85
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.